The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex
Status:
Completed
Trial end date:
1995-02-01
Target enrollment:
Participant gender:
Summary
To determine the safety and usefulness of zidovudine (AZT) for the treatment of patients with
early symptomatic HIV infection or early AIDS related complex (ARC). The ability of AZT to
suppress HIV, to improve body defenses, and to prevent the occurrence or development of AIDS
or advanced ARC is being evaluated.
In one human study, patients with AIDS or advanced ARC who received AZT had fewer
life-threatening infections, improved in weight and performance, and lived longer than
patients who received a placebo (inactive medication). Further studies are needed because
toxic effects associated with the use of AZT were noted and the long-term effectiveness and
toxicity of AZT are still unknown. It is also unknown if AZT will benefit patients with less
severe HIV infections such as early ARC or PGL.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)